23andMe will resume (limited) testing for health issues

23andMe, the company that benefited greatly with some favor from Google, suffered a massive setback when the FDA stepped in and shutdown its genetic health screening service. At the time, users could pay $99 to spit in a vial and, some time later, access their genetic data parsed to include details about their personal health. Those details included things like …